Global Cancer Biomarker Market Forecast 2017-2025KEY FINDINGS
The global cancer biomarker market is expected to grow at a CAGR of 14.07% between the years 2017- 2025, generating a net worth of $33026 million by the end of 2025. Some of the important drivers for the global biomarker market include encouragement by the FDA for biomarker development, the adoption of western lifestyles in developing countries, heavy investments by government and private funds for cancer-related research, etc. At present, the genetic and genomic biomarkers are the leading revenue generating segment of the market
The Global cancer biomarker market is segmented on the basis of the Discovery and Diagnostics and on the basis of the Diseases. The discovery and diagnostics segment is sub-divided into Biomarker discovery and Diagnostics. The biomarkers discovery is further sub-segmented into imaging, genetic methods, protein methods, and metabolomics; whereas the Diagnostic market is sub-segmented into proteomics, genetic and genomic markers, DNA microarrays, immunohistochemical tests, immunoassays, pharmacogenomics, molecular diagnostic assays, monoclonal antibodies, flow cytometry, stem cell markers etc. The Diseases segment is further sub-segmented into various types of cancers such as breast cancer, lung cancer, colorectal cancer, cervical cancer, prostate cancer, etc
The global cancer biomarker market is geographically segmented into North America (U.S. & Canada), Asia-Pacific (India, China, Japan, Australia, South Korea, and Rest of APAC), Europe (United Kingdom, Germany, Italy, France, Spain, rest of Europe) and the Rest of World (Latin America, Middle East and North Africa and Rest of Africa). The North American region is the most dominant region in the global market, with the United States acting as the major contributor. Moreover, the Asia-Pacific region is anticipated to be the fastest growing regional market owing to the increasing prevalence of cancer in the region.
Some of the noted companies in the global market are Abbott Laboratories, Agendia N.V, Affymetrix, Inc.(Acquired By Thermofisher), Agilent Technologies, Inc, Becton Dickinson And Company, Astellas Pharma Inc, Clarient, Inc. (Acquired By Neogenomics Laboratories), Illumina, Inc, Diadexus Inc (Acquired By Diazyme Laboratories), Qiagen N.V, Roche Diagnostics Ltd, Aureon Biosciences, Inc, Biomoda Inc and Ambrilia Biopharma Inc.